Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.72 |
| ▸ | RAF1 | P04049 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.60 |
| ▸ | ALDH1B1 | P30837 | 1/20 | 0.60 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | STS | P08842 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | ACLY | P53396 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL959726 | 0.90 | MAP2K1 (0.72) | MAP2K1RAF1ALDH1A1ALDH1A2ALDH1B1 | |
| SCHEMBL963453 | 0.86 | MAP2K1 (0.68) | MAP2K1RAF1ALDH1A1ALDH1A2ALDH1B1 | |
| SCHEMBL961916 | 0.85 | MAP2K1 (0.61) | MAP2K1RAF1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL958789 | 0.84 | MAP2K1 (1.00) | MAP2K1RAF1 | |
| SCHEMBL958482 | 0.84 | MAP2K1 (0.85) | MAP2K1RAF1ALDH1A1ALDH1A2ALDH1B1 | |
| SCHEMBL970190 | 0.84 | MAP2K1 (0.70) | MAP2K1RAF1ALDH1A1ALDH1A2ALDH1B1 | |
| SCHEMBL958783 | 0.84 | RAB9A (0.58) | MAP2K1RAF1ALDH1A1KDM4ESTS | |
| SCHEMBL962007 | 0.84 | MAP2K1 (0.98) | MAP2K1RAF1 | |
| SCHEMBL960796 | 0.84 | MAP2K1 (0.98) | MAP2K1RAF1 | |
| SCHEMBL962747 | 0.83 | RAF1 (0.57) | MAP2K1RAF1ALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994318-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994318-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994318-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7872142-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-18 | — | — | US | disclosed |
| US-7872142-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100197917-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197917-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197917-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100174076-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-08 | — | — | US | disclosed |
| US-20100174076-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-08 | — | — | US | disclosed |
| US-7709664-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-04 | — | — | US | disclosed |
| US-7709664-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-04 | — | — | US | disclosed |
| US-7709664-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-04 | — | — | US | disclosed |
| US-7026491-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-04-11 | — | — | US | disclosed |
| US-20060020138-A1 | Coumarin derivatives useful as TNFalpha inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-01-26 | — | — | US | disclosed |
| US-20050014705-A1 | Coumarin derivatives useful as tnf alpha inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2002008217-A2 | COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014705-A1 | Coumarin derivatives useful as tnf alpha inhibitors | TNF, NFKBIA, TNFRSF1A | MAP2K1 3709/4885RAF1 623/4885ALDH1A1 1457/4885 |
| US-20100197917-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | TNF, NFKBIA, TNFRSF1A | MAP2K1 3808/4885RAF1 699/4885ALDH1A1 1402/4885 |
| US-20100174076-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | TNF, NFKBIA, TNFRSF1A | MAP2K1 3808/4885RAF1 699/4885ALDH1A1 1402/4885 |
| US-20060020138-A1 | Coumarin derivatives useful as TNFalpha inhibitors | TNF, NFKBIA, TNFRSF1A | MAP2K1 3811/4885RAF1 1087/4885ALDH1A1 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.